Genes, BRCA2

"Genes, BRCA2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human chromosome 13 at locus 13q12.3. Mutations in this gene predispose humans to breast and ovarian cancer. It encodes a large, nuclear protein that is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev 2000;14(11):1400-6)

Descriptor ID	D024522
MeSH Number(s)	G05.360.340.024.340.375.249.105 G05.360.340.024.340.415.400.105
Concept/Terms	Genes, BRCA2 Genes, BRCA2 BRCA2 Genes Gene, BRCA2 BRCA2 Gene

Below are MeSH descriptors whose meaning is more general than "Genes, BRCA2".

Biological Sciences [G]
Genetic Phenomena [G05]
Genetic Structures [G05.360]
Genome [G05.360.340]
Genome Components [G05.360.340.024]
Genes [G05.360.340.024.340]
Genes, Neoplasm [G05.360.340.024.340.375]
Genes, Tumor Suppressor [G05.360.340.024.340.375.249]
Genes, BRCA2 [G05.360.340.024.340.375.249.105]
Genes, Recessive [G05.360.340.024.340.415]
Genes, Tumor Suppressor [G05.360.340.024.340.415.400]
Genes, BRCA2 [G05.360.340.024.340.415.400.105]

Below are MeSH descriptors whose meaning is related to "Genes, BRCA2".

Below are MeSH descriptors whose meaning is more specific than "Genes, BRCA2".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Genes, BRCA2" by people in this website by year, and whether "Genes, BRCA2" was a major or minor topic of these publications.

Bar chart showing 11 publications over 8 distinct years, with a maximum of 2 publications in 2014 and 2018 and 2022

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2004	1	0	1
2014	1	1	2
2015	1	0	1
2016	0	1	1
2017	1	0	1
2018	1	1	2
2020	1	0	1
2022	0	2	2

Below are the most recent publications written about "Genes, BRCA2" by people in Profiles.

Kotsopoulos J, Zamani N, Rosen B, McLaughlin JR, Risch HA, Kim SJ, Sun P, Akbari MR, Narod SA. Impact of germline mutations in cancer-predisposing genes on long-term survival in patients with epithelial ovarian cancer. Br J Cancer. 2022 09; 127(5):879-885.

View in: PubMed
D?az-Zabala H, Guo X, Ping J, Wen W, Shu XO, Long J, Lipworth L, Li B, Fadden MK, Pal T, Blot WJ, Cai Q, Haiman CA, Palmer JR, Sanderson M, Zheng W. Evaluating breast cancer predisposition genes in women of African ancestry. Genet Med. 2022 07; 24(7):1468-1475.

View in: PubMed
Kotsopoulos J, Karlan B, Gronwald J, Hall E, Moller P, Tung N, Zakalik D, Foulkes WD, Rosen B, Neuhausen SL, Sun P, Lubinksi J, Narod SA. Long-term outcomes following a diagnosis of ovarian cancer at the time of preventive oophorectomy among BRCA1 and BRCA2 mutation carriers. Int J Gynecol Cancer. 2020 06; 30(6):825-830.

View in: PubMed
Hollingsworth J, Lau A, Tone A, Kollara A, Allen L, Colgan TJ, Dube V, Rosen B, Murphy KJ, Greenblatt EM, Feigenberg T, Virtanen C, Brown TJ. BRCA1 Mutation Status and Follicular Fluid Exposure Alters NF?B Signaling and ISGylation in Human Fallopian Tube Epithelial Cells. Neoplasia. 2018 07; 20(7):697-709.

View in: PubMed
Dutil J, Godoy L, Rivera-Lugo R, Arroyo N, Albino E, Negr?n L, Monteiro AN, Matta JL, Echenique M. No Evidence for the Pathogenicity of the BRCA2 c.6937?+?594T>G Deep Intronic Variant: A Case-Control Analysis. Genet Test Mol Biomarkers. 2018 Feb; 22(2):85-89.

View in: PubMed
McGee J, Giannakeas V, Karlan B, Lubinski J, Gronwald J, Rosen B, McLaughlin J, Risch H, Sun P, Foulkes WD, Neuhausen SL, Kotsopoulos J, Narod SA. Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted? Gynecol Oncol. 2017 05; 145(2):346-351.

View in: PubMed
Childs EJ, Chaffee KG, Gallinger S, Syngal S, Schwartz AG, Cote ML, Bondy ML, Hruban RH, Chanock SJ, Hoover RN, Fuchs CS, Rider DN, Amundadottir LT, Stolzenberg-Solomon R, Wolpin BM, Risch HA, Goggins MG, Petersen GM, Klein AP. Association of Common Susceptibility Variants of Pancreatic Cancer in Higher-Risk Patients: A PACGENE Study. Cancer Epidemiol Biomarkers Prev. 2016 07; 25(7):1185-91.

View in: PubMed
Kotsopoulos J, Rosen B, Fan I, Moody J, McLaughlin JR, Risch H, May T, Sun P, Narod SA. Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status. Gynecol Oncol. 2016 Jan; 140(1):42-7.

View in: PubMed
Zhen DB, Rabe KG, Gallinger S, Syngal S, Schwartz AG, Goggins MG, Hruban RH, Cote ML, McWilliams RR, Roberts NJ, Cannon-Albright LA, Li D, Moyes K, Wenstrup RJ, Hartman AR, Seminara D, Klein AP, Petersen GM. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet Med. 2015 Jul; 17(7):569-77.

View in: PubMed
Vyarvelska I, Rosen B, Narod SA. Should hysterectomy complement prophylactic salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers? Gynecol Oncol. 2014 Aug; 134(2):219-21.

View in: PubMed

People

Explore

Similar Concepts

Top Journals